BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 24, Issue 29
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (10255)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.
Item 
Count 
PDF528
WORD234
HTML4646
Figures (1-2)1051
Tables (1-6)797
 Sum=7256
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1115
Download1886
 Sum=3001
Aug 7, 2018 (publication date) through Nov 26, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Aug 7, 2018; 24(29): 3281-3292
Published online Aug 7, 2018. doi: 10.3748/wjg.v24.i29.3281
Table 1 Baseline characteristics of 154 gallbladder cancer patients who underwent potential curative cholecystectomy n (%)
CharacteristicPatients (n = 154)
Age (yr)64 (29-85)
≤ 6056 (36.4)
> 6098 (63.6)
Sex
Male63 (40.9)
Female91 (59.1)
Cholecystolithiasis
Absent79 (51.3)
Present75 (48.7)
Diabetes
Absent116 (75.3)
Present38 (24.7)
Jaundice
Absent129 (83.8)
Present25 (8.9)
Blood groups
A43 (27.9)
B56 (36.4)
AB9 (5.8)
O46 (29.9)
Pathological types
Adenosquamous carcinoma3 (1.9)
Adenocarcinoma150 (97.4)
Papillocarcinoma1 (0.6)
Degree of differentiation
Poor60 (39.0)
Moderate-well94 (61.0)
Resection margin status
Negative96 (62.3)
Positive58 (37.7)
Maximum tumor diameter (cm)3 (0.2-13)
≤ 2.4568 (44.2)
> 2.4586 (55.8)
T stage
Tis-T1a10 (6.5)
T1b-T2b29 (18.8)
T3103 (66.9)
T412 (7.8)
N stage
098 (63.6)
147 (30.5)
29 (5.8)
Distant metastasis
Absent142 (92.2)
Present12 (7.8)
TNM stage
0-Istage16 (10.4)
IIA-IIB stage16 (10.4)
IIIA-IIIB stage92 (59.7)
IVA-IVB stage30 (19.5)
CA199 (U/mL)69.3 (0.6-10524)
≤ 3966 (42.9)
> 3988 (57.1)
Fibrinogen concentration (g/L)3.54 (1.71-7.47)
≤ 3.4775 (48.7)
> 3.4779 (51.3)
Albumin levels (g/L)41.0 (20.0-50.0)
≤ 40.578 (50.6)
> 40.576 (49.4)
FAR0.09 (0.04-0.25)
≤ 0.0871 (46.1)
> 0.0883 (53.9)
FAR: Fibrinogen to albumin ratio.
Full Size Table
Table 2 Correlation between fibrinogen concentration and clinicopathological characteristics in gallbladder cancer patients n (%)
CharacteristicsFibrinogen concentration
P value
≤ 3.47 g/L (n = 75)> 3.47 g/L (n = 79)
Age (yr)
≤ 6031 (20.1)25 (16.2)0.243
> 6044 (28.6)54 (35.1)
Sex
Male33 (21.4)30 (19.5)0.513
Female42 (27.3)49 (31.8)
Cholecystolithiasis
Absent38 (24.7)41 (26.6)0.878
Present37 (24.0)38 (24.7)
Diabetes
Absent57 (37.0)59 (38.3)0.850
Present18 (11.7)20 (13.0)
Jaundice
Absent68 (44.2)61 (39.6)0.029
Present7 (4.5)18 (11.7)
Blood groups
A19 (12.3)24 (15.6)0.145
B33 (21.4)23 (14.9)
AB2 (1.3)7 (4.5)
O21 (13.6)25 (16.2)
Pathological types
Adenosquamous carcinoma0 (0)3 (1.9)0.142
Adenocarcinoma75 (48.7)75 (48.7)
Papillocarcinoma0 (0)1 (0.6)
Degree of differentiation
Poor23 (14.9)37 (24.0)0.048
Moderate-well52 (33.8)42 (27.3)
Resection margin status
Negative56 (36.4)40 (26.4)0.003
Positive19 (12.3)39 (25.3)
Maximum tumor diameter (cm)
≤ 2.4534 (22.1)34 (22.1)0.871
> 2.4541 (26.6)45 (29.2)
T stage
Tis-T1a8 (5.2)2 (1.3)< 0.001
T1b-T2b22 (14.3)7 (4.5)
T343 (27.9)60 (39.0)
T42 (1.3)10 (6.5)
N stage
N050 (32.5)48 (31.2)0.748
N121 (13.6)26 (16.9)
N24 (2.6)5 (3.2)
Distant metastasis
Absent69 (44.8)73 (47.4)0.925
Present6 (3.9)6 (3.9)
TNM stage
0-Istage12 (7.8)4 (2.6)0.011
IIA-IIB stage12 (7.8)4 (2.6)
IIIA-IIIB stage39 (25.3)53 (34.4)
IVA-IVB stage12 (7.8)18 (11.7)
CA199 (U/mL)
≤ 3941 (26.6)25 (16.2)0.005
> 3934 (22.1)54 (35.1)
Albumin levels (g/L)
≤ 40.532 (20.8)44 (28.6)0.111
> 40.543 (27.9)35 (22.7)
FAR
≤ 0.0859 (38.3)12 (7.8)< 0.001
> 0.0816 (10.4)67 (43.5)
FAR: Fibrinogen to albumin ratio.
Full Size Table
Table 3 Correlation between albumin levels and clinicopathological characteristics in gallbladder cancer patients n (%)
CharacteristicsAlbumin levels
P value
≤ 40.5g/L(n = 76)> 40.5 g/L(n = 78)
Age (yr)
≤ 6022 (14.3)34 (22.1)0.067
> 6054 (35.1)44 (28.6)
Sex
Male28 (18.2)35 (22.7)0.330
Female48 (31.2)43 (27.9)
Cholecystolithiasis
Absent34 (22.1)45 (29.2)0.147
Present42 (27.3)33 (21.4)
Diabetes
Absent53 (34.4)63 (40.9)0.136
Present23 (14.9)15 (9.7)
Jaundice
Absent54 (35.1)75 (48.7)< 0.001
Present22 (14.3)3 (1.9)
Blood groups
A20 (13.0)23 (14.9)0.046
B34 (22.1)22 (14.3)
AB6 (7.9)3 (3.8)
O16 (21.1)30 (19.5)
Pathological types
Adenosquamous carcinoma0 (0)3 (1.9)0.137
Adenocarcinoma75 (48.7)75 (48.7)
Papillocarcinoma1 (0.6)0 (0.0)
Degree of differentiation
Poor36 (23.4)24 (15.6)0.047
Moderate-well40 (26.0)54 (35.1)
Resection margin status
Negative39 (25.3)57 (37.0)0.008
Positive37 (24.0)21 (13.6)
Maximum tumor diameter (cm)
≤ 2.4536 (23.4)32 (20.8)0.516
> 2.4540 (26.0)46 (29.9)
T stage
Tis-T1a2 (1.3)8 (5.2)0.021
T1b-T2b9 (5.8)20 (13.0)
T358 (37.7)45 (29.2)
T47 (4.5)5 (3.2)
N stage
N045 (29.2)53 (34.4)0.403
N125 (16.2)22 (14.3)
N26 (3.9)3 (1.9)
Distant metastasis
Absent67 (43.5)75 (48.7)0.077
Present9 (5.8)3 (1.9)
TNM stage
0-Istage3 (1.9)13 (8.4)0.007
IIA-IIB stage6 (3.9)10 (6.5)
IIIA-IIIB stage46 (29.9)46 (29.9)
IVA-IVB stage21 (13.6)9 (5.8)
CA199 (U/mL)
≤ 3924 (15.6)42 (27.3)0.006
> 3952 (33.8)36 (23.4)
Fibrinogen concentration (g/L)0.111
≤ 3.47g/L32 (20.8)43 (27.9)
> 3.47 g/L44 (28.6)35 (22.7)
FAR
≤ 0.0821 (13.6)50 (32.5)< 0.001
> 0.0855 (35.7)28 (18.2)
FAR: Fibrinogen to albumin ratio.
Full Size Table
Table 4 Correlation between FAR and clinicopathological characteristics in gallbladder cancer patients n (%)
CharacteristicsFAR
P value
≤ 0.08(n = 71)> 0.08(n = 83)
Age (yr)
≤ 6032 (20.8)24 (15.6)0.045
> 6039 (25.3)59 (38.3)
Sex
Male30 (19.5)33 (21.4)0.870
Female41 (26.6)50 (32.5)
Cholecystolithiasis
Absent37 (24.0)42 (27.3)0.873
Present34 (22.1)41 (26.6)
Diabetes
Absent56 (36.4)60 (39.0)0.357
Present15 (9.7)23 (14.9)
Jaundice
Absent67 (43.5)62 (40.3)< 0.001
Present4 (2.6)21 (13.6)
Blood groups
A22 (14.3)21 (13.6)0.148
B28 (18.2)28 (18.2)
AB1 (0.6)8 (5.2)
O20 (13.0)26 (16.9)
Pathological types
Adenosquamous carcinoma0 (0)3 (1.9)0.173
Adenocarcinoma71 (46.1)79 (51.3)
Papillocarcinoma0 (0)1 (0.6)
Degree of differentiation
Poor18 (11.7)42 (27.3)0.002
Moderate-well53 (34.4)41 (26.6)
Resection margin status
Negative55 (35.7)41 (26.6)< 0.001
Positive16 (10.4)42 (27.3)
Maximum tumor diameter (cm)
≤ 2.4537 (24.0)31 (20.1)0.075
> 2.4534 (22.1)52 (33.8)
T stage
Tis-T1a8 (5.2)2 (1.3)< 0.001
T1b-T2b24 (15.6)5 (3.2)
T336 (23.4)67 (43.5)
T43 (1.9)9 (5.8)
N stage
N048 (31.2)50 (32.5)0.623
N119 (12.3)28 (18.2)
N24 (2.6)5 (3.2)
Distant metastasis
Absent68 (44.2)74 (48.1)0.145
Present3 (1.9)9 (5.8)
TNM stage
0-Istage14 (9.1)2 (1.3)< 0.001
IIA-IIB stage14 (9.1)2 (1.3)
IIIA-IIIB stage35 (22.7)57 (37.0)
IVA-IVB stage8 (5.2)22 (14.3)
CA199 (U/mL)
≤ 3943 (27.9)23 (14.9)< 0.001
> 3928 (18.2)60 (39.0)
Fibrinogen concentration (g/L)
≤ 3.47g/L59 (38.3)16 (10.4)< 0.001
> 3.47 g/L12 (7.8)67 (43.5)
Albumin levels (g/L)
≤ 40.5g/L21 (13.6)55 (35.7)< 0.001
> 40.5 g/L50 (32.5)28 (18.2)
Full Size Table
Table 5 Univariate analysis of overall survival in gallbladder cancer patients
CharacteristicsHR (95%CI)P value
Age (yr)1.473 (0.973-2.230)0.067
≤ 60
> 60
Sex0.995 (0.670-1.477)0.981
Male
Female
Cholecystolithiasis1.198 (0.814-1.764)0.360
Absent
Present
Diabetes1.028 (0.651-1.623)0.906
Absent
Present
Jaundice2.598 (1.644-4.106)< 0.001
Absent
Present
Blood groups-0.113
A
B
AB
O
Pathological types-0.165
Adenosquamous carcinoma
Adenocarcinoma
Papillocarcinoma
Degree of differentiation1.527 (1.031-2.261)0.035
Poor
Moderate-well
Resection margin status3.683 (2.468-5.496)< 0.001
Negative
Positive
Maximum tumor diameter (cm)1.101 (0.744-1.630)0.631
≤ 2.45
> 2.45
T stage-< 0.001
Tis-T1a
T1b-T2b
T3
T4
N stage-< 0.001
0
1
2
Distant metastasis2.550 (1.388-4.684)0.003
Absent
Present
TNM stage-< 0.001
0-Istage
IIA-IIB stage
IIIA-IIIB stage
IVA-IVB stage
CA199 (U/mL)3.125 (2.010-4.858)< 0.001
≤ 39
> 39
Fibrinogen concentration (g/L)2.795 (1.853-4.214)< 0.001
≤ 3.47
> 3.47
Albumin levels (g/L)0.391(0.259-0.590)< 0.001
≤ 40.5
> 40.5
FAR4.626(2.987-7.165)< 0.001
≤ 0.08
> 0.08
FAR: Fibrinogen to albumin ratio; HR: Hazard ratio; CI: Confidence interval.
Full Size Table
Table 6 Multivariate analysis for overall survival in gallbladder cancer patients
CharacteristicsHR (95%CI)WaldP value
Resection margin status2.343 (1.532-3.581)< 0.001
Negative
Positive
TNM stage8.5950.035
IIA-IIB stage/0-1stage1.209 (0.287-5.095)0.0670.796
IIIA-IIIB stage/0-1 stage3.401 (1.033-11.202)4.0510.044
IVA-IVB stage/0-1 stage4.014 (1.142-14.107)4.6960.030
FAR2.813 (1.765-4.484)< 0.001
≤ 0.08
> 0.08
Albumin levels (g/L)0.595 (0.385-0.921)0.020
≤ 40.5
> 40.5
FAR: Fibrinogen to albumin ratio; HR: Hazard ratio; CI: Confidence interval.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345